[go: up one dir, main page]

MA33821B1 - Préparation aérosol pour copd (bronchopneumathie chronique obstructive) - Google Patents

Préparation aérosol pour copd (bronchopneumathie chronique obstructive)

Info

Publication number
MA33821B1
MA33821B1 MA34964A MA34964A MA33821B1 MA 33821 B1 MA33821 B1 MA 33821B1 MA 34964 A MA34964 A MA 34964A MA 34964 A MA34964 A MA 34964A MA 33821 B1 MA33821 B1 MA 33821B1
Authority
MA
Morocco
Prior art keywords
copd
sprayer
preparation
patients
administration
Prior art date
Application number
MA34964A
Other languages
Arabic (ar)
English (en)
Inventor
Sauro Bonelli
Francesca Usberti
Enrico Zambelli
Original Assignee
Chiesi Farma Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42046446&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA33821(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chiesi Farma Spa filed Critical Chiesi Farma Spa
Publication of MA33821B1 publication Critical patent/MA33821B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65B—MACHINES, APPARATUS OR DEVICES FOR, OR METHODS OF, PACKAGING ARTICLES OR MATERIALS; UNPACKING
    • B65B31/00—Packaging articles or materials under special atmospheric or gaseous conditions; Adding propellants to aerosol containers
    • B65B31/04—Evacuating, pressurising or gasifying filled containers or wrappers by means of nozzles through which air or other gas, e.g. an inert gas, is withdrawn or supplied
    • B65B31/06—Evacuating, pressurising or gasifying filled containers or wrappers by means of nozzles through which air or other gas, e.g. an inert gas, is withdrawn or supplied the nozzle being arranged for insertion into, and withdrawal from, the mouth of a filled container and operating in conjunction with means for sealing the container mouth
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65B—MACHINES, APPARATUS OR DEVICES FOR, OR METHODS OF, PACKAGING ARTICLES OR MATERIALS; UNPACKING
    • B65B31/00—Packaging articles or materials under special atmospheric or gaseous conditions; Adding propellants to aerosol containers
    • B65B31/10—Adding propellants in solid form to aerosol containers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dispersion Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Mechanical Engineering (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne des préparations aérosol stables comprenant du bromure de glycopyrronium conçues pour être administrées à des patients souffrant de bronchopneumopathie chronique obstructive (copd) et d'autres affections respiratoires.
MA34964A 2009-12-23 2012-06-14 Préparation aérosol pour copd (bronchopneumathie chronique obstructive) MA33821B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09015980 2009-12-23
PCT/EP2010/070478 WO2011076842A2 (fr) 2009-12-23 2010-12-22 Préparation aérosol pour copd (bronchopneumopathie chronique obstructive)

Publications (1)

Publication Number Publication Date
MA33821B1 true MA33821B1 (fr) 2012-12-03

Family

ID=42046446

Family Applications (1)

Application Number Title Priority Date Filing Date
MA34964A MA33821B1 (fr) 2009-12-23 2012-06-14 Préparation aérosol pour copd (bronchopneumathie chronique obstructive)

Country Status (31)

Country Link
US (5) US20110150783A1 (fr)
EP (1) EP2515854B1 (fr)
JP (1) JP5800829B2 (fr)
KR (1) KR101747474B1 (fr)
CN (1) CN102665680B (fr)
AU (2) AU2010334858A1 (fr)
CA (1) CA2785317C (fr)
CL (1) CL2012001668A1 (fr)
CO (1) CO6551734A2 (fr)
CY (1) CY1115109T1 (fr)
DK (1) DK2515854T3 (fr)
EA (1) EA021604B1 (fr)
ES (1) ES2464520T3 (fr)
GE (1) GEP20166479B (fr)
HR (1) HRP20140550T1 (fr)
IL (1) IL220534A0 (fr)
MA (1) MA33821B1 (fr)
MX (1) MX340264B (fr)
MY (1) MY156950A (fr)
NZ (1) NZ600789A (fr)
PE (1) PE20121467A1 (fr)
PH (1) PH12012501063A1 (fr)
PL (1) PL2515854T3 (fr)
PT (1) PT2515854E (fr)
RS (1) RS53355B (fr)
SG (1) SG181870A1 (fr)
SI (1) SI2515854T1 (fr)
TN (1) TN2012000261A1 (fr)
UA (1) UA106098C2 (fr)
WO (1) WO2011076842A2 (fr)
ZA (1) ZA201204613B (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2515854E (pt) 2009-12-23 2014-05-27 Chiesi Farma Spa Formulação de aerossol para dpoc
WO2011076841A2 (fr) * 2009-12-23 2011-06-30 Chiesi Farmaceutici S.P.A. Polythérapie destinée à la bronchopneumopathie chronique obstructive
DK2515855T6 (da) 2009-12-23 2023-06-06 Chiesi Farm Spa Kombinationsterapi til COPD
CA2935305C (fr) * 2013-12-30 2022-07-12 Chiesi Farmaceutici S.P.A. Composition de solution d'aerosol stable, mise sous pression, de combinaison de bromure de glycopyrronium et de formoterol
TN2016000262A1 (en) 2013-12-30 2017-10-06 Chiesi Farm Spa Stable pressurised aerosol solution composition of glycopyrronium bromide and formoterol combination.
EP3383366B2 (fr) 2015-12-04 2024-06-05 Mexichem Fluor S.A. de C.V. Composition pharmaceutique
PE20191043A1 (es) * 2016-09-19 2019-08-06 Mexichem Fluor Sa De Cv Composicion farmaceutica
WO2020084549A1 (fr) * 2018-10-25 2020-04-30 Glenmark Specialty S.A. Composition de nébulisation comprenant du glycopyrrolate et du formotérol
CN115989032A (zh) 2020-07-31 2023-04-18 化学研究有限公司 用于吸入施用的组合疗法
CN112051346A (zh) * 2020-09-24 2020-12-08 珠海瑞思普利生物制药有限公司 一种同时测定茚达特罗和格隆溴铵含量的hplc方法
JP2023546025A (ja) 2020-10-09 2023-11-01 キエシ・フアルマチエウテイチ・ソチエタ・ペル・アチオニ 加圧定量吸入器のための医薬製剤
CA3257044A1 (fr) 2022-05-27 2023-11-30 Chiesi Farmaceutici S.P.A. Formulation pharmaceutique pour aérosol-doseur sous pression

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2956062A (en) 1959-02-26 1960-10-11 Robins Co Inc A H Esters of amino alcohols
DE69324161T2 (de) 1992-12-09 1999-10-28 Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield Stabilisierte medizinische aerosollösungen
DK1102579T3 (da) 1998-08-04 2003-07-14 Jago Res Ag Medicinske aerosolformuleringer
IT1317720B1 (it) 2000-01-07 2003-07-15 Chiesi Farma Spa Dispositivo per la somministrazione di aerosol dosati pressurizzati inpropellenti idrofluoroalcani.
GB0008660D0 (en) 2000-04-07 2000-05-31 Arakis Ltd The treatment of respiratory diseases
UA73986C2 (uk) * 2000-05-22 2005-10-17 К'Єзі Фармачеутічі С.П.А. АЕРОЗОЛЬНА КОМПОЗИЦІЯ, ЩО МІСТИТЬ <font face="Symbol">b</font>2-АДРЕНЕРГІЧНИЙ АГОНІСТ ТРИВАЛОЇ ДІЇ, ДОЗУЮЧИЙ ІНГАЛЯТОР ПІД ТИСКОМ ТА СПОСІБ ЙОГО ЗАПОВНЕННЯ
US20060257324A1 (en) * 2000-05-22 2006-11-16 Chiesi Farmaceutici S.P.A. Pharmaceutical solution formulations for pressurised metered dose inhalers
EP1372608B1 (fr) * 2001-03-30 2007-10-10 Jagotec Ag Formulations aerosol medicales
US6667344B2 (en) 2001-04-17 2003-12-23 Dey, L.P. Bronchodilating compositions and methods
EP1321159A1 (fr) 2001-12-21 2003-06-25 CHIESI FARMACEUTICI S.p.A. Dispositif d'actionnement pour inhalateur doseur pressurisé avec orifices percés par laser
ATE465712T1 (de) 2002-03-01 2010-05-15 Chiesi Farma Spa Ultrafeine zusammensetzungen von formoterol
CA2510043A1 (fr) 2002-12-16 2004-07-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Formulations de solutions aux hfc contenant du tiotropium
CA2550841C (fr) * 2004-02-06 2012-10-02 Meda Pharma Gmbh & Co. Kg Nouvelle combinaison d'anticholinergique et de beta-mimetiques pour le traitement de maladies respiratoires
GB0410399D0 (en) 2004-05-10 2004-06-16 Arakis Ltd The treatment of respiratory disease
GB0613161D0 (en) * 2006-06-30 2006-08-09 Novartis Ag Organic Compounds
EP1894568A1 (fr) 2006-08-31 2008-03-05 Novartis AG Composées pharmaceutiques destinées au traitement des maladies inflammatoires ou obstructives des bronches
WO2009051818A1 (fr) 2007-10-18 2009-04-23 Stiefel Research Australia Pty Ltd Formulations topiques de glycopyrrolate
CA2764867C (fr) * 2009-06-09 2016-05-17 Elevation Pharmaceuticals, Inc. Traitement d'une maladie pulmonaire obstructive chronique par administration de beta 2 agoniste nebulise ou d'une combinaison de beta 2 agoniste nebulise et d'anticholinergique
CN102695496B (zh) * 2009-12-23 2014-10-01 奇斯药制品公司 用于copd的气雾剂制剂
WO2011076841A2 (fr) 2009-12-23 2011-06-30 Chiesi Farmaceutici S.P.A. Polythérapie destinée à la bronchopneumopathie chronique obstructive
DK2515855T6 (da) * 2009-12-23 2023-06-06 Chiesi Farm Spa Kombinationsterapi til COPD
PT2515854E (pt) * 2009-12-23 2014-05-27 Chiesi Farma Spa Formulação de aerossol para dpoc
CA2807406C (fr) * 2010-08-03 2018-12-11 Chiesi Farmaceutici S.P.A. Formulation pharmaceutique comprenant un inhibiteur de phosphodiesterase
GB201200525D0 (en) 2011-12-19 2012-02-29 Teva Branded Pharmaceutical Prod R & D Inc An inhalable medicament
CA2935305C (fr) * 2013-12-30 2022-07-12 Chiesi Farmaceutici S.P.A. Composition de solution d'aerosol stable, mise sous pression, de combinaison de bromure de glycopyrronium et de formoterol
TN2016000262A1 (en) 2013-12-30 2017-10-06 Chiesi Farm Spa Stable pressurised aerosol solution composition of glycopyrronium bromide and formoterol combination.

Also Published As

Publication number Publication date
NZ600789A (en) 2014-09-26
CA2785317A1 (fr) 2011-06-30
WO2011076842A3 (fr) 2011-12-01
US20150306026A1 (en) 2015-10-29
MX2012006879A (es) 2012-07-04
US11590074B2 (en) 2023-02-28
US12357568B2 (en) 2025-07-15
DK2515854T3 (da) 2014-05-26
PH12012501063A1 (en) 2013-02-04
EP2515854A2 (fr) 2012-10-31
ES2464520T3 (es) 2014-06-03
UA106098C2 (uk) 2014-07-25
EP2515854B1 (fr) 2014-03-19
CA2785317C (fr) 2018-02-27
MY156950A (en) 2016-04-15
PL2515854T3 (pl) 2014-08-29
US20110150783A1 (en) 2011-06-23
CN102665680A (zh) 2012-09-12
SG181870A1 (en) 2012-07-30
RS53355B (sr) 2014-10-31
EA021604B1 (ru) 2015-07-30
CY1115109T1 (el) 2016-12-14
KR20120120160A (ko) 2012-11-01
KR101747474B1 (ko) 2017-06-14
JP2013515695A (ja) 2013-05-09
CL2012001668A1 (es) 2012-12-07
ZA201204613B (en) 2013-09-25
BR112012015336A2 (pt) 2016-03-15
HRP20140550T1 (hr) 2014-07-18
PE20121467A1 (es) 2012-11-07
CO6551734A2 (es) 2012-10-31
JP5800829B2 (ja) 2015-10-28
SI2515854T1 (sl) 2014-07-31
US10806701B2 (en) 2020-10-20
US20210000738A1 (en) 2021-01-07
GEP20166479B (en) 2016-05-25
HK1174568A1 (en) 2013-06-14
AU2010334858A1 (en) 2012-07-12
EA201290374A1 (ru) 2013-01-30
MX340264B (es) 2016-07-04
TN2012000261A1 (en) 2013-12-12
IL220534A0 (en) 2012-08-30
AU2016234894B2 (en) 2018-02-22
US20250262151A1 (en) 2025-08-21
CN102665680B (zh) 2014-07-30
AU2016234894A1 (en) 2016-10-13
PT2515854E (pt) 2014-05-27
WO2011076842A2 (fr) 2011-06-30
US20230157951A1 (en) 2023-05-25

Similar Documents

Publication Publication Date Title
MA33821B1 (fr) Préparation aérosol pour copd (bronchopneumathie chronique obstructive)
HUS2100018I1 (hu) Hatóanyagok légúti beadására alkalmas készítmények és ezekkel kapcsolatos eljárások
WO2013021199A3 (fr) Compositions pharmaceutiques
MA33823B1 (fr) Polythérapie pour bronchopneumopathie chronique obstructive (copd)
AR067639A1 (es) Medicamentos pulverulentos que contienen tiotropio y salmetrol, asi como lactosa como excipiente
JP2010132695A5 (fr)
ATE524450T1 (de) 5-phenyl-isoxazol-3-carboxamid-derivate als trpv1-modulatoren
EP2582676A4 (fr) Modulateurs allostériques positifs du récepteur m1 de l&#39;amide tétrahydroquinoline
ATE421325T1 (de) Kombination von methylxanthinverbindungen und steroiden zur behandlung chronischer atemwegserkrankungen
BRPI0819932A2 (pt) composição, uso de uma composição, dispositivo nebulizador, inalador ou intranasal, processos para produzir uma composição farmacêutica e uma composição polipeptídica, e, uso de um tampão fisiologicamente aceitável.
EA201200876A1 (ru) Новые антагонисты рецептора ccr2 и их применение
WO2012074231A3 (fr) Composition pharmaceutique comprenant du furoate de mométasone et du chlorhydrate d&#39;azélastine pour une administration nasale
ECSP10010265A (es) Sales farmaceuticamente aceptables de (3-{[[3-(6-amino-2-butoxi-8-oxo-7,8 dihidro-9h-purin-9-il)propil](3-morfolin-4 ilpropil)amino]metil}fenil)
MX2009008363A (es) Combinacion de un antagonista de receptor muscarinico y un agonista de receptor adrenergico beta 2.
UA100777C2 (ru) Вдыхаемые частички, содержащие тиотропий
IL213620A0 (en) Preparation and therapeutic applications of (2s, 3r)-n-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl]-3,5-difluorobenzamide
EA201201397A1 (ru) Ингалятор, содержащий расслаиваемую блистерную упаковку
MD4369B1 (ro) Utilizarea glicopirolatului pentru tratarea tahicardiei, doză unică, dispozitiv de administrare, metodă de tratament şi profilaxie a tahicardiei
EA201590019A1 (ru) Ингаляторы сухого порошка, содержащие носитель, отличный от лактозы
UY30935A1 (es) Combinacion:-antagonista del receptor de quimioquina 1 (ccr1) -agonista del receptor de glucocorticoides- opcionalmente agonista b(beta)2, -composicion farmacéutica conteniéndola -aplicaciones.
WO2011076840A3 (fr) Préparation aérosol pour bronchopneumopathie chronique obstructive
EA201201389A1 (ru) Ингалятор, создающий турбулентность
EP2323656A4 (fr) Produit pharmaceutique constitué d un antagoniste du récepteur muscarinique et d un agoniste du récepteur adrénergique bêta 2
MX2010012019A (es) Producto farmaceutico que comprende un antagonista receptor muscarinico y un agonista de adrenoceptor beta2.
EA029678B9 (ru) Четвертичные соли пиперидиния